MasKidney is committed to fostering transparency and communication with our investors as we work towards our mission of improving kidney health and wellness through our innovative gene therapy.

For more information or to discuss investment opportunities, please reach out to our Investor Relations team at Burns McClellan. We value your interest and look forward to building a successful partnership.

Contact Lee Roth of Burns McClellan: [email protected]